These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 37397500)

  • 1. Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
    Yang S; Liu Y; Zhang S; Wu F; Liu D; Wu Q; Zheng H; Fan P; Su N
    Front Pharmacol; 2023; 14():1145587. PubMed ID: 37397500
    [No Abstract]   [Full Text] [Related]  

  • 2. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Colacci M; Fralick J; Odutayo A; Fralick M
    Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
    Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-Glucose Co-Transporter-2 Inhibitors in Non-Diabetic Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis.
    Zheng H; Liu M; Li S; Shi Q; Zhang S; Zhou Y; Su N
    Front Endocrinol (Lausanne); 2021; 12():706914. PubMed ID: 34484120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
    Chen L; Xue Q; Yan C; Tang B; Wang L; Zhang B; Zhao Q
    Front Endocrinol (Lausanne); 2023; 14():1256548. PubMed ID: 38027214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
    Li CX; Liu LY; Zhang CX; Geng XH; Gu SM; Wang YQ; Liu H; Xie Q; Liang S
    Front Endocrinol (Lausanne); 2023; 14():1238399. PubMed ID: 37701900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials.
    Gong C; Shen SC; Zhang K; Zhou L; Shen JJ; Zhao JY; Ding SG; Ma LK; Gao H
    Front Cardiovasc Med; 2022; 9():926979. PubMed ID: 36312269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis.
    Dutta S; Kumar T; Singh S; Ambwani S; Charan J; Varthya SB
    J Family Med Prim Care; 2022 Mar; 11(3):927-940. PubMed ID: 35495849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: A systematic review and meta-analysis.
    Al-Hindi B; Mohammed MA; Mangantig E; Martini ND
    J Am Pharm Assoc (2003); 2024; 64(1):9-26.e6. PubMed ID: 37844733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in COVID-19-infected patients: A systematic review of case reports.
    Khedr A; Hennawi HA; Khan MK; Eissa A; Mir M; Rauf I; Nitesh J; Surani S; Khan SA
    World J Clin Cases; 2023 Aug; 11(24):5700-5709. PubMed ID: 37727728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
    Donnan JR; Grandy CA; Chibrikov E; Marra CA; Aubrey-Bassler K; Johnston K; Swab M; Hache J; Curnew D; Nguyen H; Gamble JM
    BMJ Open; 2019 Feb; 9(1):e022577. PubMed ID: 30813108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Zhou H; Peng W; Li F; Wang Y; Wang B; Ding Y; Lin Q; Zhao Y; Pan G; Wang X
    Front Cardiovasc Med; 2022; 9():875327. PubMed ID: 35600478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Diabetic Ketoacidosis Associated with Sodium Glucose Cotransporter-2 Inhibitors: A Network Meta-Analysis and Meta-Regression.
    Sridharan K; Sivaramakrishnan G
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541972
    [No Abstract]   [Full Text] [Related]  

  • 18. The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials.
    Wang X; Fu R; Liu H; Ma Y; Qiu X; Dong Z
    Ann Palliat Med; 2021 Jun; 10(6):6467-6481. PubMed ID: 34118855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
    Wang H; Yang J; Chen X; Qiu F; Li J
    Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
    Liu H; Sridhar VS; Perkins BA; Rosenstock J; Cherney DZI
    Curr Diab Rep; 2022 Jul; 22(7):317-332. PubMed ID: 35633439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.